Difference of Oral Mucositis in Hospitalized Cancer Patients Receiving Chemotherapy

Mi Hyang Park; Jeong Sook Park

doi:10.5388/aon.2013.13.2.76

Journal List > Asian Oncol Nurs > v.13(2) > 1081796

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Park: Difference of Oral Mucositis in Hospitalized Cancer Patients Receiving Chemotherapy

Original Article

Asian Oncology Nursing 2013; 13(2): 76-84.

Published online: 30 June 2013

DOI: https://doi.org/10.5388/aon.2013.13.2.76

Difference of Oral Mucositis in Hospitalized Cancer Patients Receiving Chemotherapy

Mi Hyang Park, Jeong Sook Park

College of Nursing, Keimyung University, Daegu, Korea.

Address reprint requests to: Park, Jeong Sook. College of Nursing, Keimyung University, 2800 Dalgubeoldaero, Dalseogu, Daegu 704701, Korea. Tel: +82535803907, Fax: +82535803904, jsp544@kmu.ac.kr

Received 23 January 2013 Accepted 10 June 2013

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

This study was designed to investigate the difference of oral mucositis in hospitalized cancer patients receiving chemotherapy according to characteristics.

Methods

Data were collected from March 1 to April 25 2012 using questionnaires, and the participants were 177. The Oral Assessment Guide (OAG) by observation and The Oral Mucositis Daily Questionnaire (OMDQ) by self-report were used to measure oral mucositis. The data were analyzed using SPSS 18.0.

Results

Moderate to severe oral mucositis measured by OAG observation were 94.9% in hospitalized cancer patients receiving chemotherapy, frequently complaints of mouth and throat soreness measured by OMDQ was 42.4%, and intensity of mouth and throat soreness measured by OMDQ was 0.65 out of 10. There were statistically significant differences in the prevalence of oral mucositis according to nutrition state, frequency of chemotherapy, experience of oral examination, combination treatment, and number of chemotherapeutic agents.

Conclusion

Many hospitalized cancer patients receiving chemotherapy experienced oral mucositis. Cancer patients receiving chemotherapy with poor nutritional status, more frequent chemotherapy and combination treatments should have a more meticulous oral care. So there needs to be an appropriate assessment tool and prevention protocol for oral mucositis that considers related factors.

Keywords: Chemotherapy, Cancer Patients, Oral Mucositis

Figures and Tables

Table 1

Prevalence Oral Mucositis in Hospitalized Cancer Patients Receiving Chemotherapy (N=177)

OAG=Oral Assessment Guide; OMDQ-MTS=Oral Mucositis Daily Questionnaire-Mouth Throat Soreness; OM=Oral mucositis; MTS=Mouth Throat Soreness.

Table 2

Correlation between OAG, OMDQ-MTS Frequency and OMDQ-MTS Intensity (N=177)

^*p<.001.

OAG=Oral Assessment Guide; OMDQ-MTS=Oral Mucositis Daily Questionnaire-Mouth Throat Soreness.

Table 3

Differences of Oral Mucositis according to General Characteristics (N=177)

OM=Oral mucositis; OAG=Oral Assessment Guide; OMDQ-MTS=Oral Mucositis Daily Questionnaire-Mouth Throat Soreness.

Table 4

Differences of Oral Mucositis according to Oral Condition (N=177)

OAG=Oral Assessment Guide; OMDQ-MTS=Oral Mucositis Daily Questionnaire-Mouth Throat Soreness.

Table 5

Differences of Oral Mucositis according to Cancer-related Characteristics (N=177)

^*OAG score according to frequency of chemotherapy: Dunnett T3 further test: b,c,d,e>a; OMDQ-MTS (frequency) score according to frequency of chemotherapy: Scheffe further test: e>a; ^†OAG score according to type of treatment: Scheffe further test: b>a.

CTX=Chemotherapy; CCRT=chemotherapy combined radiation therapy; OP=Operation; ANC=Absolute Neutrophil Count; WBC=White Blood Cell; OAG=Oral Assessment Guide; OMDQ-MTS=Oral Mucositis Daily Questionnaire-Mouth Throat Soreness.

Notes

This article is a condensed form of the first author's master's thesis from Keimyung University.

References

1. National Cancer Information Center. National cancer registration statistics. Accessed February 2, 2012. http://www.cancer.go.kr/ncic/cics_f/01/011/index.html.

2. National Cancer Information Center. Understanding of Cancer. Accessed February 23, 2012. http://www.cancer.go.kr/ncic/cics_a/03/031/0312/index.html.

3. Yabro CH, Frogge MH, Goodman M, Groenwald SL. Cancer nursing principles and practice. 5th ed. Sudbury: Jones and Bartlett Publishers;2000.

4. Viens P, Petit T, Yovine A. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol. 2006; 17(3):429–436.

5. Bruya MA, Madeira NP, Powell N. Stomatitis after chemotherapy. Am J Nurs. 1975; 75:1349–1352.

6. Turhal NS, Erdal S, Karacy S. Efficacy of treatment to relieve mucositis-induced discomfort. Support Care Cancer. 2000; 8:55–58.

7. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003; 39(2):91–100.

8. Byun YS, Kim AK. The survey of mouth care among cancer patient received chemotherapy. J Korean Acad Fundam Nurs. 1995; 2(2):115–130.

9. Cheng KK, Goggins WB, Lee WS, Thompson DR. Risk factors for oral mucositis in children undergoing chemotherapy: a matchedcase-control study. Oral Oncol. 2008; 44:1019–1025.

10. Cheng KK, Lee WS, Li CH, Goggins WB, Thompson DR, Yuen HL, et al. Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy. Oral Oncol. 2011; 47:153–162.

11. Eilers J, Berger A, Peterson MC. Development, testing and application of the oral assessment guide. Oncol Nurs Forum. 1988; 15(3):325–330.

12. Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest. 2002; 20:793–800.

13. Quinn B, Stone R, Uhlenhopp M, McCann S, Blijlevens N. Ensuring accurate oral mucositis assessment in the European group for blood and marrow transplantation prospective oral mucositis audit. Eur J Oncol Nurs. 2007; 11:S10–S18.

14. Choi SE, Kim HS. Reliability and validity of patient self-reported daily questionnaire on oral Mucositis in acute leukemic patients under chemotherapy. J Korean Biol Nurs Sci. 2010; 12(3):148–156.

15. Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, et al. Reliability and validity of a patient silf-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patient undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006; 37:393–401.

16. Song CE, So HS, Ju D, Kim EJ. Randomized controlled trial for preventing stomatitis and discomfort among acute leukemic patients. J Korean Oncol Nurs. 2011; 11:33–40.

17. Faber MV. Mucositis in cancer patients. In : Nevidijon BM, Sowers KW, editors. A nurse guide to cancer care. Philadelphia, PA: Lippincott Williams & Wilkins;2000. p. 311–317.

18. Darwish AM, Salama MA, Basiouny NS, Arafa NM. Effect of chlorhexidine in prevention of oral lesions in leukemic children receiving chemotherapy. J Am Sci. 2011; 7(7):985–996.

19. Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. Oncol Nurs Forum. 2006; 33:931–936.

20. Weaver C, Schiech L, Held-Warmkessel J, Kedziera P, Haney E, Dilullo G, et al. Risk for unplanned hospital readmission of patients with cancer: results of a retrospective medical record review. Oncol Nurs Forum. 2006; 33:E44–E52.

21. Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting evidence into practice: Evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008; 12:141–152.

22. Chun HW. Analysis of factors for relationship between oral disease and chronic disease [dissertation]. Jeonbuk: Wonkwang Univ.;2011.

23. Kim HM. Management of chemotherapy-related toxicity: nutrition support during chemotherapy. Symp Korean Soc Clin Oncol. 2005; 3:23–33.

24. Sonis ST. Mucositis as a biological process: a new bypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34:39–43.

25. Graham KM, Pecoraro DA, Vontura M, Meyer CC. Reducing the incidence of stomatitis using a quality assessment and improvement approach. Cancer Nurs. 1993; 16:117–122.

26. Kim ES. A study on perceived oral health, oral health promotion and dental impact of daily living. J Korean Acad Dent Health. 2000; 24:145–157.

27. Eaton LH, Tipton JM. Putting evidence into practice: improving oncology patient outcomes. Pittsburgh, PA: Oncology Nursing Society;2009.

28. Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009; 45(12):1015–1020.

29. Chun SM, Lee HJ, Kim MS. Effect of cold oral gargling on the oral discomfort among patients receiving chemotherapy. J Korean Oncol Nurs. 2007; 7:68–78.

30. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003; 98:1531–1539.

TOOLS

Similar articles